Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?

Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent cytotoxicity on B cells expressing the CD20 marker. In this review, we analyse the efficacy and possible pitfalls of rituximab to treat nephrotic syndromes by taking into account pharmacological consid...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Vecchio, Lucia, Allinovi, Marco, Rocco, Paolo, Brando, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709396/
https://www.ncbi.nlm.nih.gov/pubmed/34945143
http://dx.doi.org/10.3390/jcm10245847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709396/
https://www.ncbi.nlm.nih.gov/pubmed/34945143
http://dx.doi.org/10.3390/jcm10245847

Ejemplares similares